Almost one-fifth of patients with opioid use disorder (OUD) in a large health care system died during a four-year follow-up period, according to a study published in the Journal of Addiction Medicine.

A new lawsuit alleges that infamous blood-testing company Theranos Inc. misled company directors about its laboratory-testing practices; used a secret shell company to buy commercial lab equipment; and improperly created rosy financial projections for investors, according to an article in the Wall Street Journal.

As high drug prices make national headlines, the challenge of providing sick children with the kind of medications they can take and tolerate—often by creating liquid formulations of drugs that are already on the market—is seen by some pharma companies as a lucrative opportunity, according to an article posted on the Kaiser Health News (KHN) webs

Stopping payments for the Patient Protection and Affordable Care Act (PPACA) cost-sharing program could save $10 billion but would cost an additional $12.3 billion in premium tax credits––an estimated net increase of $2.3 billion (23%) in federal spending on marketplace subsidies––in 2018 if insurers continue to participate in PPACA marketplaces, accordin

Use of statins to prevent the recurrence of a heart attack after the first such incidence is a generally accepted practice guideline, but its effectiveness is muted because of nonadherence, according to a study in JAMA Cardiology.

An international team at the University of Exeter Medical School in the United Kingdom and at the University of Alberta in Canada has discovered an underlying defect in brain cells that may lead to multiple sclerosis (MS), providing a potential target for future treatments. The new study was published in the journal Neuroinflammation.

The FDA has cleared Renflexis (infliximab-abda, Samsung Bioepis/Merck), a biosimilar product referencing Remicade (infliximab, Janssen), across all eligible indications. The product will be marketed in the United States by Merck.

Renflexis, a tumor necrosis factor (TNF) blocker, has the following indications:

With cash in their pockets, big pharma companies are on the prowl for promising medications being developed at smaller firms to treat patients with nonalcoholic steatohepatitis (NASH), a progressive fatty liver disease that is on its way to becoming the number one cause of liver transplants by 2020, according to a Reuters report.

Partly due to the Patient Protection and Affordable Care Act (PPACA), the U.S. health-care industry now employs one in nine Americans––up from one in 12 in 2000, according to a report from Kaiser Health News. Moreover, an estimated 35% of the nation’s job growth has come from health care since the “great recession” hit in early 2007.

The Trump administration continues to push for a House vote this week to dismantle the Patient Protection and Affordable Care Act (PPACA), which the president said is “in serious trouble,” according to a Bloomberg report.

Some states have established programs, mostly dependent on reinsurance, in an effort to make Obamacare more palatable for already skittish insurance plans, the Wall Street Journal reports.

Research led by scientists at the University of Birmingham in the United Kingdom has identified a new cause of hypertension that could lead to major changes in managing the disease.

The FDA has issued a complete response letter (CRL) regarding the new drug application for CCP-07 (Vernalis/Tris Pharma), an extended-release cough-and-cold medication. A CRL is issued when the FDA has completed its review of a new drug application and questions remain that preclude the application’s approval at that time.

Valeant Pharmaceuticals International has announced that, following the approval of its Patient Access and Pricing Committee (PAPC), it has decided to list brodalumab injection (Siliq) at $3,500 per month, which the company says is the lowest price for an injectable biologic psoriasis treatment currently on the market.

As House Republicans try to reach agreement on a bill to overhaul the Patient Protection and Affordable Care Act (PPACA), they may be ready to let states make the ultimate decision about whether to keep a key consumer provision in the act that conservatives say is raising insurance costs, according to a report from Kaiser Health News (KHN).